Capricor Therapeutics signs contingent lease for new San Diego headquarters pending FDA approval of Deramiocel.
Capricor Therapeutics has secured a lease for approximately 171,000 square feet in San Diego to serve as its new headquarters. The move is contingent on the company receiving FDA approval for its Duchenne muscular dystrophy therapy, Deramiocel, by December 31, 2026. This headquarters expansion includes new manufacturing cleanrooms, R&D labs, and offices, designed to support a manufacturing scale-up as the company moves toward commercialization. The lease is structured around regulatory milestones, providing rent abatements and tenant improvement support. The upcoming FDA advisory committee meeting on July 29, 2026, will be a critical catalyst for the company's long-term manufacturing footprint. While the move underscores the company's commitment to the therapy, investors are cautioned that the company's success remains tied to the primary risk of the August 2026 FDA verdict. If Deramiocel fails to secure timely approval, the company may face the option to terminate the lease, highlighting the tight link between regulatory success and the company's operational growth.